| Title | Development of a vaccine against leishmaniasis. |
|---|---|
| Supervisors | not found cdes10 Martin Wiese |
| Research Area | Drug discovery, formulation and delivery, Health and Well-being |
| Description | Leishmaniasis is a serious health threat. Current there is no clinical vaccine. This project will build on pervious studies to develop a recombinant protein vaccine to protects against leishmaniasis. Leishmaniasis is a disease caused by infection with the protozoan parasite Leishmania, which is transmitted by female sand flies. The type of disease caused by the parasite depends on the infecting species and the host’s immune response but three main forms occur, cutaneous, mucocutaneous and visceral leishmaniasis. The World Health Organisation estimates that 350 million people, living in 98 countries, are at risk of contracting leishmaniasis, and each year approximately 1.5 million new cases of cutaneous and 500,000 of visceral leishmaniasis are reported. In terms of disease burden, leishmaniasis is responsible for 2,357,000 DALYs (Disability-Adjusted Life Years) lost due to ill effects caused by the disease. We have shown that is it possible to protect against Leishmania infection by using gamma glutamyl cysteine synthetase as a vaccine candidate. We will continue our studies to develop an oral on inhalable anti-Leishmania vaccine. |
| Techniques Used | Recombinant DNA technology, aseptic tissue culture techniques, parasite maintenance, IVIS imaging and immunological assays e.g. immune responses using ELISA assays, lymphocyte proliferations assays, Greiss assay. |
| References | 1. Sundar S, Singh OP, Chakravarty J. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. Expert Rev Anti Infect Ther. 2018, 16:805-812. 2. Moafi M, Rezvan H, Sherkat R, Taleban R. Leishmania Vaccines Entered in Clinical Trials: A Review of Literature.Int J Prev Med. 2019 Jun 7;10:953. Henriquez et al. (2010) Vaccination with recombinant Leishmania donovani gamma-glutamylcysteine synthetase fusion protein protects against L. donovani infection. J Parasitol.96(5):929-36 |
| Conditions | Applicants should possess or be about to obtain a 1st class or 2:1 Honours degree or equivalent in a relevant discipline in addition to receipt of satisfactory references and an IELTS score of 6.5 where appropriate. |
| Bench Fee | Running costs of £10000 p.a. will be associated with this project in addition to University tuition fees. |
| Apply Now |